Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
46 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Premature Labor (Tocolysis) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Premature Labor (Tocolysis) - Pipeline Review, H1 2015', provides an overview of the Premature Labor (Tocolysis)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Premature Labor (Tocolysis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Premature Labor (Tocolysis) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Premature Labor (Tocolysis) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Premature Labor (Tocolysis) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Premature Labor (Tocolysis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Premature Labor (Tocolysis) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Premature Labor (Tocolysis) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Premature Labor (Tocolysis) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Premature Labor (Tocolysis) Overview 6 Therapeutics Development 7 Pipeline Products for Premature Labor (Tocolysis) - Overview 7 Pipeline Products for Premature Labor (Tocolysis) - Comparative Analysis 8 Premature Labor (Tocolysis) - Therapeutics under Development by Companies 9 Premature Labor (Tocolysis) - Therapeutics under Investigation by Universities/Institutes 10 Premature Labor (Tocolysis) - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Unknown Stage Products 14 Premature Labor (Tocolysis) - Products under Development by Companies 15 Premature Labor (Tocolysis) - Products under Investigation by Universities/Institutes 16 Premature Labor (Tocolysis) - Companies Involved in Therapeutics Development 17 Actavis plc 17 GlaxoSmithKline plc 18 Kissei Pharmaceutical Co., Ltd. 19 ObsEva SA 20 Premature Labor (Tocolysis) - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 AT-814 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 bedoradrine sulfate - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Drug for Postpartum Depression and Premature Labor - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 OBE-001 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 OBE-002 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Progesterone Second Generation - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 retosiban - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Small Molecule to Agonize Progesterone Receptor for Preterm Birth - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Premature Labor (Tocolysis) - Recent Pipeline Updates 39 Premature Labor (Tocolysis) - Dormant Projects 41 Premature Labor (Tocolysis) - Discontinued Products 42 Premature Labor (Tocolysis) - Product Development Milestones 43 Featured News & Press Releases 43 Aug 17, 2007: MediciNova Reports Phase Ib Clinical Study Results For MN-221 A Novel Treatment For Preterm Labor 43 Mar 14, 2005: MediciNova Initiates A Phase I Clinical Trial With MN-221 43 Mar 24, 2004: MediciNova Acquires Phase II Premature Labor Compound 44 Appendix 45 Methodology 45 Coverage 45 Secondary Research 45 Primary Research 45 Expert Panel Validation 45 Contact Us 45 Disclaimer 46
List of Tables Number of Products under Development for Premature Labor (Tocolysis), H1 2015 7 Number of Products under Development for Premature Labor (Tocolysis) - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Late Stage Development, H1 2015 11 Comparative Analysis by Clinical Stage Development, H1 2015 12 Comparative Analysis by Early Stage Development, H1 2015 13 Comparative Analysis by Unknown Stage Development, H1 2015 14 Products under Development by Companies, H1 2015 15 Products under Investigation by Universities/Institutes, H1 2015 16 Premature Labor (Tocolysis) - Pipeline by Actavis plc, H1 2015 17 Premature Labor (Tocolysis) - Pipeline by GlaxoSmithKline plc, H1 2015 18 Premature Labor (Tocolysis) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2015 19 Premature Labor (Tocolysis) - Pipeline by ObsEva SA, H1 2015 20 Assessment by Monotherapy Products, H1 2015 21 Number of Products by Stage and Target, H1 2015 23 Number of Products by Stage and Mechanism of Action, H1 2015 25 Number of Products by Stage and Route of Administration, H1 2015 27 Number of Products by Stage and Molecule Type, H1 2015 29 Premature Labor (Tocolysis) Therapeutics - Recent Pipeline Updates, H1 2015 39 Premature Labor (Tocolysis) - Dormant Projects, H1 2015 41 Premature Labor (Tocolysis) - Discontinued Products, H1 2015 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.